JNJ

168.33

+0.26%↑

NVS

117.53

+0.08%↑

ABT

128.38

+0.92%↑

MDT

92.19

-0.07%↓

ELV.US

288.71

-0.9%↓

JNJ

168.33

+0.26%↑

NVS

117.53

+0.08%↑

ABT

128.38

+0.92%↑

MDT

92.19

-0.07%↓

ELV.US

288.71

-0.9%↓

JNJ

168.33

+0.26%↑

NVS

117.53

+0.08%↑

ABT

128.38

+0.92%↑

MDT

92.19

-0.07%↓

ELV.US

288.71

-0.9%↓

JNJ

168.33

+0.26%↑

NVS

117.53

+0.08%↑

ABT

128.38

+0.92%↑

MDT

92.19

-0.07%↓

ELV.US

288.71

-0.9%↓

JNJ

168.33

+0.26%↑

NVS

117.53

+0.08%↑

ABT

128.38

+0.92%↑

MDT

92.19

-0.07%↓

ELV.US

288.71

-0.9%↓

Search

Pliant Therapeutics Inc

Closed

1.46 -8.18

Overview

Share price change

24h

Current

Min

1.46

Max

1.6

Key metrics

By Trading Economics

Income

-6.4M

-56M

Employees

171

EBITDA

-10M

-59M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+403.14% upside

Dividends

By Dow Jones

Next Earnings

5 sie 2025

Market Stats

By TradingEconomics

Market Cap

98M

Previous open

9.64

Previous close

1.46

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Pliant Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 lip 2025, 23:57 UTC

Acquisitions, Mergers, Takeovers

EQT: To Spend Y407.82B for Tender Offer

29 lip 2025, 23:56 UTC

Acquisitions, Mergers, Takeovers

EQT: Tender Offer Price Is Y5,700 a Share

29 lip 2025, 23:54 UTC

Acquisitions, Mergers, Takeovers

EQT To Start Tender Offer for Fujitec

29 lip 2025, 23:50 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 lip 2025, 23:36 UTC

Market Talk

Gold Steady Ahead of FOMC Decision -- Market Talk

29 lip 2025, 22:57 UTC

Market Talk

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 lip 2025, 22:50 UTC

Market Talk

Mondelez Warns of Price Increases in North America -- Market Talk

29 lip 2025, 22:44 UTC

Acquisitions, Mergers, Takeovers

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 lip 2025, 22:41 UTC

Acquisitions, Mergers, Takeovers

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 lip 2025, 22:41 UTC

Acquisitions, Mergers, Takeovers

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 lip 2025, 22:35 UTC

Earnings

IGO Maintains Nova Life of Mine Production Guidance

29 lip 2025, 22:35 UTC

Earnings

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 lip 2025, 22:35 UTC

Earnings

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 lip 2025, 22:34 UTC

Earnings

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 lip 2025, 22:34 UTC

Earnings

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 lip 2025, 22:34 UTC

Market Talk
Earnings

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 lip 2025, 22:33 UTC

Earnings

IGO Had A$279.7 Million of Cash at End-June

29 lip 2025, 22:33 UTC

Earnings

IGO 4Q Underlying Free Cash A$2.4 Million

29 lip 2025, 22:33 UTC

Earnings

IGO FY Sales Revenue A$512.5 Million

29 lip 2025, 22:33 UTC

Earnings

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 lip 2025, 22:32 UTC

Earnings

IGO FY Nickel Production 17,173 Tons

29 lip 2025, 22:32 UTC

Earnings

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 lip 2025, 22:32 UTC

Earnings

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 lip 2025, 22:31 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

29 lip 2025, 22:31 UTC

Market Talk
Earnings

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 lip 2025, 22:31 UTC

Earnings

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 lip 2025, 22:31 UTC

Earnings

IGO FY Spodumene Production 1.48 Million Tons

29 lip 2025, 22:30 UTC

Earnings

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 lip 2025, 22:30 UTC

Earnings

IGO 4Q Underlying Ebitda A$62 Million

29 lip 2025, 22:22 UTC

Earnings

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Price Target

By TipRanks

403.14% upside

12 Months Forecast

Average 8 USD  403.14%

High 17 USD

Low 3 USD

Based on 6 Wall Street analysts offering 12 month price targets forPliant Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

6 ratings

1

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.